Group 1 - The Annual General Meeting (AGM) for Zip Co Limited was officially opened by the Chair of the Board, Diane Smith-Gander, confirming that a quorum was present [1] - The meeting is being conducted virtually, with a note that technology issues may require a short recess or adjournment [2] - Diane Smith-Gander acknowledged the traditional custodians of the land, the Gadigal people of the Eora Nation, and paid respects to their Elders [3] Group 2 - The meeting introduced key members of the Board and Zip executives, including CEO Cynthia Scott and Independent Nonexecutive Directors [4] - There was a mention of a technical difficulty affecting the attendance of Kevin Moss, who is expected to join virtually from the United States [4]

Core Insights - The company has announced a joint venture in Saudi Arabia, highlighting its expansion efforts in the region [2] - Recent initiatives in artificial intelligence have been introduced, indicating a focus on technological advancement [2] Company Updates - The CEO, Dwight Egan, will provide updates on the company's diagnostics technology, clinical pathway, and commercialization efforts [1] - The fireside chat aims to discuss several interesting topics related to the company's current status and future plans [5]

Summary of Co-Diagnostics Fireside Chat - November 05, 2025 Company Overview - **Company**: Co-Diagnostics (NasdaqCM:CODX) - **Industry**: Molecular Diagnostics - **Technology**: Develops, manufactures, and markets advanced diagnostics technologies that are accurate, affordable, fast, easy to use, and non-invasive [3][6] Key Announcements - **Joint Venture in Saudi Arabia**: Recently announced, aimed at expanding market presence in a large, underserved market [1][19] - **Artificial Intelligence Initiatives**: New business unit focused on AI to enhance diagnostic capabilities [1][25] Core Technology and Products - **Co-Primers Technology**: Enables multiplex testing for multiple indications simultaneously, such as the forthcoming ABCR test for flu A, flu B, COVID-19, and RSV [7][8] - **CODIAX PCR Pro**: A miniaturized PCR device designed to be accessible and affordable, targeting large diagnostic gaps in markets like India and Saudi Arabia [10][11] - **Clinical Trials**: Upcoming trials for ABCR, human papillomavirus, and tuberculosis tests [11][39] Market Strategy - **Focus on Emerging Markets**: Significant infrastructure established in India with 15 tests currently sold; plans to leverage joint ventures in Saudi Arabia and India for growth [18][19] - **U.S. Market Dynamics**: Different regulatory pathways for tests; initial focus on point-of-care markets such as pharmacies and clinics [22][23] Financial Insights - **Cost-Effective Solutions**: The CODIAX PCR device priced between $300 to $500, significantly lower than competitors' devices costing $10,000 to $20,000 [33][34] - **Margin Profile**: Anticipated margins of approximately 30% on instruments and 70% to 80% on consumables [37][38] Future Milestones - **Clinical Trials**: Introduction of tests into clinical trials in the U.S., India, and Africa [39] - **SPAC Transaction for Cosara**: Plans to pursue a SPAC transaction to capitalize on the infrastructure built in India [29][31] Investment Opportunities and Risks - **Undervalued Stock**: Company believes its stock is undervalued due to market misinterpretation of its ongoing COVID-related initiatives [41][42] - **Sustainable Business Model**: Focus on providing affordable diagnostics with ongoing revenue from consumables [42] Additional Insights - **AI Integration**: Ongoing development of AI models to enhance diagnostic accuracy and operational efficiency [26][28] - **Global Health Impact**: Commitment to improving healthcare access and quality, particularly in underserved regions [44] This summary encapsulates the key points discussed during the fireside chat, highlighting the company's strategic direction, technological advancements, and market opportunities.

Accessibility StatementSkip Navigation SALT LAKE CITY, Oct. 31, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its third quarter 2025 financial results on Thursday, November 13, 2025, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results with analysts. Manage ...

Accessibility StatementSkip Navigation SALT LAKE CITY, Oct. 30, 2025 /PRNewswire/ --Â Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will host a virtual fireside chat on Wednesday, November 5, 2025 at 11:00 am ET. Join Dwight Egan. CEO of Co-Dx, for an update on the Company's growth initiatives, including its recently announced definitive agreement with ...

Core Insights - The article emphasizes the importance of staying updated with international news, particularly in the context of economic developments and market trends [1] Group 1 - The Economic Times provides comprehensive coverage of US, UK, Canada, and international news, highlighting significant events that could impact the economy [1] - The platform encourages users to download its news app for daily updates, indicating a shift towards digital news consumption [1] - The focus on economic news suggests a growing interest in how global events influence financial markets and investment opportunities [1]

Market Overview - U.S. stocks traded higher, with the Dow Jones index gaining over 100 points, up 0.30% to 47,688.42, while NASDAQ rose 0.45% to 23,744.57, and S&P 500 fell slightly by 0.01% to 6,874.13 [1] - Information technology shares increased by 0.8%, while real estate stocks decreased by 2.1% [1] Company Performance - United Parcel Service Inc (UPS) reported third-quarter earnings of $1.74 per share, exceeding the analyst consensus estimate of $1.31 per share, and quarterly sales of $21.400 billion, surpassing the estimate of $20.832 billion [2] Commodity Market - Oil prices fell by 1.5% to $60.40, gold decreased by 1.9% to $3,942.30, silver dropped by 0.6% to $46.510, and copper fell by 0.7% to $5.1375 [3] European Market - European shares were mostly lower, with the eurozone's STOXX 600 down 0.3%, Spain's IBEX 35 Index down 0.1%, London's FTSE 100 up 0.1%, Germany's DAX 40 down 0.2%, and France's CAC 40 down 0.2% [4] Asian Market - Asian markets closed lower, with Japan's Nikkei 225 down 0.58%, Hong Kong's Hang Seng index down 0.33%, China's Shanghai Composite down 0.22%, and India's BSE Sensex down 0.18% [5] Stock Movements - Vsee Health Inc shares surged 235% to $2.07 after receiving U.S. Department of Health and Human Services authority to operate at the FedRAMP High level [7] - TEN Holdings Inc shares increased by 139% to $0.67, while 707 Cayman Holdings Ltd shares rose by 47% to $0.44 [7] - Co-Diagnostics Inc shares fell by 54% to $0.58 following a $7 million registered direct offering at $0.55 per share [7] - SMX (Security Matters) PLC shares decreased by 24% to $4.43, and OceanPal Inc shares fell by 23% to $1.70 [7] Economic Indicators - The FHFA house price index rose by 0.4% month-over-month in August, while the S&P CoreLogic Case-Shiller 20-City Home Price Index increased by 1.6% year-over-year, below market expectations of a 1.9% gain [8] - U.S. private businesses created an average of 14,250 jobs per week during the four weeks ending on October 11 [9]

Core Insights - Co-Diagnostics (Co-Dx) has entered into a definitive agreement with Arabian Eagle Manufacturing to establish a joint venture named CoMira Diagnostics for the distribution of polymerase chain reaction (PCR) platforms in Saudi Arabia and 18 other countries in the MENA region [1][2] Group 1: Joint Venture Details - The joint venture will focus on the research, development, distribution, and marketing of Co-Dx's technologies and intellectual property, including the PCR point-of-care platform [1][2] - Arabian Eagle will oversee the establishment of a manufacturing facility, manage regulatory approvals, and ensure compliance with local laws as part of the joint venture [2][4] - Co-Dx will provide the joint venture with an exclusive license to utilize, produce, and market its licensed intellectual property, which includes both the upcoming PCR platform and existing laboratory-based diagnostic products [3][6] Group 2: Market Strategy and Growth Potential - The CEO of Co-Dx emphasized the importance of this agreement in expanding healthcare innovations into a region with a significant and growing market for medical devices and point-of-care diagnostics [4][5] - The Kingdom of Saudi Arabia has identified key demand drivers that are expected to support growth in the medical diagnostics sector, which Co-Dx aims to address with its advanced PCR technology [5] - CoMira is set to initiate clinical assessments for various tests, including tuberculosis and multiplex tests for Covid-19, influenza A and B, RSV, and an 8-type HPV multiplex test by the end of the year [5] Group 3: Regulatory Considerations - The companies plan to seek regulatory clearance from the Saudi Food & Drug Administration (SFDA) to facilitate market entry across the broader territory [2][6] - The Co-Dx PCR platform, which includes the PCR Pro, PCR Home, mobile app, and associated tests, is currently pending clearance from the US Food and Drug Administration (FDA) and other regulatory authorities [6]

Group 1 - Celestica Inc. reported third-quarter earnings of $1.58 per share, exceeding the analyst estimate of $1.47 per share [1] - The company's quarterly revenue reached $3.19 billion, surpassing the Street estimate of $3.01 billion [1] - Following the positive financial results, Celestica shares surged 8.3% to $326.87 in pre-market trading [1] Group 2 - TEN Holdings, Inc. gained 89.2% to $0.5294 in pre-market trading after a 5% increase on Monday [4] - Freight Technologies, Inc. surged 65.1% to $2.03 in pre-market trading after adding 5% on Monday [4] - J-Star Holding Co., Ltd rose 48% to $1.270 in pre-market trading [4] - Reliance Global Group, Inc. surged 48% to $1.41 in pre-market trading after completing the purchase of Solana and reaffirming a special cash dividend of $0.03 per share for December [4] - Founder Group Limited rose 40.3% to $0.4947 in pre-market trading after gaining 5% on Monday [4] - AtlasClear Holdings, Inc. gained 29% to $0.4893 in pre-market trading due to a 49% increase in net income at its subsidiary [4] - 374Water Inc. gained 22.3% to $0.4733 in pre-market trading after a 15% dip on Monday [4] - Pulmonx Corporation rose 16.7% to $1.82 in pre-market trading following management transition and preliminary third-quarter revenue announcement [4] Group 3 - Co-Diagnostics, Inc. tumbled 13.5% to $1.09 in pre-market trading after a significant 259% jump on Monday [4] - Rambus Inc. declined 14.3% to $97.29 in pre-market trading after announcing downbeat quarterly earnings [4] - Royalty Management Holding Corp fell 12.9% to $2.50 in pre-market trading after an 8% decline on Monday [4] - GoldMining Inc fell 9.7% to $1.21 in pre-market trading after a decline of more than 5% on Monday [4] - Galaxy Digital Inc dipped 8.8% to $37.00 in pre-market trading following a private offering of $1 billion in exchangeable senior notes [4]

Core Viewpoint - Co-Diagnostics, Inc. has entered a joint venture with Arabian Eagle Manufacturing in Saudi Arabia to develop and commercialize its diagnostic technologies across the Middle East and North Africa, aligning with Saudi Vision 2030 [1][3]. Group 1: Joint Venture Details - The joint venture will focus on research, development, manufacturing, assembly, distribution, and commercialization of Co-Dx technologies, including the upcoming Co-Dx PCR point-of-care platform [1][3]. - Financial terms of the joint venture were not disclosed [2]. - Arabian Eagle will manage local operational support, setup of the manufacturing facility, regulatory clearance, and compliance [5]. Group 2: Strategic Alignment and Market Potential - The partnership supports key pillars of Saudi Vision 2030, emphasizing technology localization, industrial diversification, and healthcare innovation [3]. - The KSA is identified as having a large and growing market for medical devices and point-of-care diagnostics, with demand drivers published by the government [5]. Group 3: Product Development and Clinical Evaluation - The new platform will include tests for infectious diseases such as tuberculosis, an 8-type HPV multiplex test, and a respiratory multiplex test for influenza A and B, COVID-19, and RSV, with clinical evaluations expected to begin before the end of 2025 [7]. - Co-Diagnostics will provide Arabian Eagle an exclusive license to use, manufacture, and commercialize its intellectual property, including the upcoming Co-Dx PCR platform and existing lab-based PCR diagnostic products [6].